Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03836547
Other study ID # 18-001832
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 19, 2019
Est. completion date September 30, 2022

Study information

Verified date October 2022
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Researchers are trying to test the effectiveness and feasibility of a multicomponent lifestyle intervention to support weight loss decreases dyspnea in obese people with chronic lung disease and clinically significant breathlessness.


Description:

Patient will be randomized to a 12-week intervention that uses the Weight watchers lifestyle program online, a Garmin Fitness Tracker, blue tooth scale and receive health coaching vs a wait-list control group.


Recruitment information / eligibility

Status Completed
Enrollment 28
Est. completion date September 30, 2022
Est. primary completion date September 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria - Age = 18 years. - BMI >=35 - Dyspnea MRC class II or greater - Diagnosis of lung disease - Signed informed consent Exclusion Criteria - BMI <35 - Pregnancy - Recent respiratory illness (within the last 6 weeks) - Recent exacerbation of chronic lung disease (within the last 6 weeks) - Already participating in a structured diet and/or exercise program - Medical contraindication to weight loss (cancer) - Medical contraindication to unsupervised exercise (unstable angina)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Coaching and Weight Loss for patients with dyspnea
Patients with lung disease and a BMI of 35 or greater who suffer from shortness of breath will be invited to participate in a study involving a commercial weight loss application with health coaching. The patients will subscribe on their own to the weight loss application. The patients will be provided with a blue tooth scale so that they may weigh themselves weekly. A health coach will call them weekly for 8 weeks.
Active Control
Participants will receive usual care for 12 weeks followed by the active intervention.

Locations

Country Name City State
United States Mayo Clinic in Florida Jacksonville Florida
United States Mayo Clinic in Rochester Rochester Minnesota
United States Mayo Clinic in Arizona Scottsdale Arizona

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Breathlessness Chronic Respiratory Questionnaire Dyspnea baseline to 12 weeks
Secondary Lean Body Mass (lbs.)using InBody 770 Scale InBody770 analyzer to define Lean Body Mass (total body weight minus weight of fat). This measure includes organs, skin, bones, water and muscle. baseline to 12 weeks
Secondary Skeletal Muscle Mass (lbs.) using InBody 770 Scale InBody770 analyzer to define skeletal muscle mass (total weight of muscle) baseline to 12 weeks
Secondary Percent Body Fat using InBody 770 Scale InBody770 analyzer to define percent body fat baseline to 12 weeks
Secondary Weight using InBody 770 Scale InBody770 analyzer to define weight baseline to 12 weeks
Secondary Body Mass Index using InBody 770 Scale InBody770 analyzer to define Body Mass Index (BMI) is weight in kilograms divided by height in meters squared. A BMI of 25 or below is considered healthy. baseline to 12 weeks
Secondary Mindful Eating Mindful Eating Questionnaire- 28 item instrument with a score range of 1-4. Higher scores are associated with lower body mass indexes. baseline to 12 weeks
Secondary Daily Steps Number of steps participant takes in a day recorded by Actigraph Activity tracker. baseline to 12 weeks
Secondary Daily Sedentary Time Actigraph Activity Tracker to determine the amount of time (minutes) spend sedentary status baseline to 12 weeks
Secondary Daily Physical Activity Actigraph Activity Tracker to define the amount of time spent in mild to moderate and vigorous physical activity define by METs baseline to 12 weeks
Secondary Exercise Capacity Six-Minute Walking Test baseline to 12 weeks
Secondary Sleep Time Measures Actigraph to measure total sleep time baseline to 12 weeks
Secondary Sleep Efficiency Time sleeping/ Time reclined baseline to 12 weeks
Secondary Disease specific quality of life Chronic Respiratory Questionnaire measures Fatigue , Emotions and Mastery and is a 20 item questionnaire with a range of 1-7. A higher score is best. baseline to 12 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06000696 - Healthy at Home Pilot
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Completed NCT04105075 - COPD in Obese Patients
Recruiting NCT05825261 - Exploring Novel Biomarkers for Emphysema Detection
Active, not recruiting NCT04075331 - Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial Phase 2/Phase 3
Terminated NCT03640260 - Respiratory Regulation With Biofeedback in COPD N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
Withdrawn NCT04210050 - Sleep Ventilation for Patients With Advanced Hypercapnic COPD N/A
Terminated NCT03284203 - Feasibility of At-Home Handheld Spirometry N/A
Recruiting NCT06110403 - Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness Phase 1/Phase 2
Active, not recruiting NCT06040424 - Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Recruiting NCT04868357 - Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program N/A
Completed NCT01892566 - Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV N/A
Completed NCT04119856 - Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD N/A
Completed NCT04485741 - Strados System at Center of Excellence
Completed NCT03626519 - Effects of Menthol on Dyspnoea in COPD Patients N/A
Recruiting NCT04860375 - Multidisciplinary Management of Severe COPD N/A

External Links